Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations

Analysts at Topeka Capital initiated coverage on shares of Signet Jewelers Limited (NYSE: SIG) with a “buy” rating. The target price for Signet Jewelers is set to $83. Signet's shares closed at $72.04 yesterday.

Benchmark initiated coverage on shares of Imax (NYSE: IMAX) with a “hold” rating. The target price for Imax is set to $29.42. Imax's shares closed at $29.70 yesterday.

FBR Capital initiated coverage on shares of Aeropostale (NYSE: ARO) with a “market perform” rating. The target price for Aeropostale is set to $10. Aeropostale's stock closed at $9.55 yesterday.

Analysts at Roth Capital initiated coverage on shares of Golden Minerals Company (NYSE: AUMN) with a “neutral” rating. The target price for Golden Minerals Company is set to $1. Golden Minerals Company's shares closed at $0.93 yesterday.

Latest Ratings for SIG

DateFirmActionFromTo
Sep 2019ReiteratesNeutral
Sep 2019MaintainsSell
Jan 2019DowngradesNeutralSell

View More Analyst Ratings for SIG
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ARO + AUMN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TORCCantor FitzgeraldDowngrades3.0
CIDMCanaccord GenuityMaintains1.5
TDGCanaccord GenuityMaintains620.0
DLPNCanaccord GenuityMaintains1.6
WBCLSADowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Autodesk Signs Agreement to Acquire Structural Fabrication and Detailing Technology from Graitec; Terms Undisclosed

Durata Data on Dalbavancin Shows Primary Endpoints Met